Efficacy of Early Administration of Tocilizumab in COVID-19 Patients

Stopped Based on interim analysis for futility and given an enrolment rate almost nil

Conditions

• COVID-19 Pneumonia

Interventions

• DRUG: Tocilizumab

Sponsor

Azienda USL Reggio Emilia - IRCCS